Imagine being imprisoned within your own thoughts, unable to express your basic needs and desires to those around you. For millions of Americans living with dementia, this is their daily reality. But one North Carolina family is finding hope in an unlikely place: artificial intelligence. Anna Lawrence, a young...
Read More
What is the state of mind uploading technology? Could it help preserve our memories? Is this idea anywhere near fruition? Let’s review what’s happening.
Read More
Global life science giant Labcorp is rolling out a test that it says can speed up a diagnosis for Alzheimer’s and thus lead to earlier intervention to fight the deadly disease.
Read More
Based on the results, in people with early symptomatic Alzheimer’s disease, Lilly says it plans to file for approval from the US Food and Drug Administration by the end of June.
Read More
The lab of Juan Song, PhD, and colleagues at the UNC School of Medicine, demonstrated the therapeutic potential of new neurons generated in adulthood for modulating the pathology and functional deficits associated with Alzheimer’s disease using rodent models.
Read More
Japan-based pharma Eisai and its US partner Biogen, which has a large campus in RTP, could receive full FDA approval for their Alzheimer’s drug by July 6, the companies announced Monday.
Read More
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Here’s what is happening.
Read More
U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh.
Read More
A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration” to approve a high-priced Alzheimer’s drug from Biogen was “rife with irregularities.”
Read More
